Merck Global Health Innovation Fund

About The Fund

Merck Global Health Innovation Fund (GHI) is a corporate venture capital fund established by Merck & Co., Inc., aiming to invest in breakthrough health care solutions. With headquarters in Whitehouse Station, New Jersey, United States, GHI is uniquely positioned within the digital health sector to leverage Merck's global presence and deep scientific understanding of biology and disease states. The fund focuses on emerging companies that are working to create value in the healthcare ecosystem by advancing the convergence of healthcare and the technologies that support health and wellness. Key investment areas include Education, BioTech, HealthTech, Fitness, Medical Devices, Hospital Services, Healthcare, Wellness, and Pharmaceutical Medicine. GHI offers funding amounts ranging from a minimum of $100,000 to a maximum of $5,000,000, with a sweet spot for investments at about $1,500,000. The fund participates mainly in Seed, Series A, and Series B financing rounds. Merck GHI operates as a Corporate Venture Capital (Corporate VC) firm and seeks to empower entrepreneurs with not only capital but also access to the vast network and resources of a multinational pharmaceutical company. The goal of Merck GHI is not only to generate financial returns but also to foster innovation that can improve the quality of life for patients worldwide. Their strategy involves identifying and funding promising healthcare technologies that can scale and integrate effectively into the broader market, thereby addressing unmet medical needs and accelerating access to health services and products.